

# ZOETIS INC.

ISIN: US98978V1035

WKN: 98978V103

Asset Class: **Stock**

## Company

2024/05/03 22:00:02



Price

**167.07**

USD

Difference

-0.10%(-0.16)



## Contact Details

ZOETIS INC. Tel: +1-973-822-7000  
-- Fax: +  
10 Sylvan Way Web: <http://www.zoetis.com>  
07054 Parsippany E-mail: -

## Company Profile

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	6,343,000,000		7,506,000,000		6,930,000,000	
Common stock capital		5,000,000		5,000,000		5,000,000
Fixed assets	7,943,000,000		7,419,000,000		6,970,000,000	
Equity capital of a company		4,991,000,000		4,403,000,000		4,544,000,000
Cash and cash equivalents	2,041,000,000		3,581,000,000		3,485,000,000	
Accrued liabilities		351,000,000		337,000,000		360,000,000
Other assets	-		-		-	
Current liabilities		1,889,000,000		3,167,000,000		1,797,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		7,406,000,000		7,355,000,000		7,559,000,000
Different income		-		-		-
Other liabilities		157,000,000		138,000,000		136,000,000
Total assets	14,286,000,000	14,286,000,000	14,925,000,000	14,925,000,000	13,900,000,000	13,900,000,000

## Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	14,100	13,800	12,100
Equity ratio	34.89%	29.49%	32.70%
Debt-equity ratio	186.58%	239.13%	205.83%

## Others

	2023	2022	2021
Tax Expense Rate	20.30%	20.52%	18.25%

# ZOETIS INC.

ISIN: US98978V1035

WKN: 98978V103

Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	8,544,000,000	8,080,000,000	7,776,000,000
<b>Net income</b>	2,344,000,000	2,114,000,000	2,037,000,000
<b>EBIT</b>	2,907,539,600	2,672,398,400	2,554,827,800
<b>Operating income before taxes</b>	2,936,000,000	2,656,000,000	2,488,000,000
<b>Cash Flow</b>	2,353,000,000	1,912,000,000	2,213,000,000
<b>Net interest income</b>	-180,000,000	-208,000,000	-250,000,000
<b>Research and development expenses</b>	614,000,000	539,000,000	508,000,000
<b>Income taxes</b>	596,000,000	545,000,000	454,000,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	565,419	546,337	599,652

## Board of Directors

## Members of Management Board

Michael McCallister	Chairman of Board of Directors
Linda Rhodes	Member of Board of Directors
Willie Reed	Member of Board of Directors
Antoinette Leatherberry	Member of Board of Directors
Frank D'Amelio	Member of Board of Directors
Gavin Hattersley	Member of Board of Directors
Gregory Norden	Member of Board of Directors
Louise Parent	Member of Board of Directors
Paul Bisaro	Member of Board of Directors
Robert Scully	Member of Board of Directors
Sanjay Khosla	Member of Board of Directors
Vanessa Broadhurst	Member of Board of Directors
Kristin Peck	Chairman of Managing Board
Ester Banque	Member of Executive Committee
Heidi Chen	Member of Executive Committee
Jamie Brannan	Member of Executive Committee
Jeanette Ferran Astorga	Member of Executive Committee
Nick Ashton	Member of Executive Committee
Rimma Driscoll	Member of Executive Committee
Robert J. Polzer	Member of Executive Committee
Roxanne Lagano	Member of Executive Committee
Wafaa Mamilli	Member of Executive Committee
Wetteny Joseph	Member of Executive Committee